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Background: Maintenance use of nonsteroidal anti-inﬂammatory
drugs (NSAIDs) is often complicated by gastropathy. In non-
NSAID users, eradication of Helicobacter pylori is associated with
decreased mucosal inﬂammation, and may halt the progression to
atrophy and intestinal metaplasia, but the continuous use of
NSAIDs may interfere with these processes.
Goal: To investigate the eﬀect of H. pylori eradication on gastric
mucosal histology during long-term NSAID use, with and without
gastroprotective therapy.
Study: Patients were eligible for inclusion if they were on long-term
NSAIDs and were H. pylori-positive on serologic testing. Patients
were randomly assigned to either eradication or placebo. Gastritis
was assessed according to the updated Sydney classiﬁcation for
activity, chronic inﬂammation, gastric glandular atrophy, intestinal
metaplasia, and H. pylori density.
Results: Biopsy specimens were available for histology of 305
patients. Of these, 48% were on chronic gastroprotective medica-
tion. Signiﬁcant less active gastritis, inﬂammation, and H. pylori
density was found in the eradication group compared with
the placebo group in both corpus and antrum (P<0.001). In the
corpus, less atrophy was found in the eradication group compared
with the placebo group.
Conclusions: H. pylori eradication in patients on long-term NSAID
therapy leads to healing of gastritis despite ongoing NSAID
therapy.
Key Words: nonsteroidal anti-inﬂammatory drugs, Helicobacter
pylori, gastritis histology, proton pump inhibitor
(J Clin Gastroenterol 2009;43:140–146)
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) arewidely prescribed for rheumatic diseases. Maintenance
use of NSAIDs is, however, often complicated by NSAID-
gastropathy, which is characterized by dyspepsia, superﬁcial
mucosal damage, gastroduodenal ulcers, and even life-
threatening ulcer complications.1 Many strategies have been
evaluated in recent years to prevent and treat gastroduodenal
ulcers and their life threatening complications in NSAID
users such as the addition of acid suppressive therapies,
treatment with selective and speciﬁc cyclooxygenase-2
inhibitors, and eradication of Helicobacter pylori.2–7
H. pylori causes continuous gastric inﬂammation in
nearly all infected persons.8 This chronic inﬂammation
persists throughout life and may lead to mucosal gland loss
or atrophic gastritis, which may precede the development
of intestinal metaplasia, dysplasia, and cancer.9,10 Although
NSAID use and H. pylori are the most common causes of
peptic ulcers and their complications, and are frequently
present in the same patients, the mechanisms of interaction
require further study.11
Although many studies have shown that eradication of
H. pylori causes resolution of active and chronic gastritis in
non-NSAID users,12–14 the eﬀect of H. pylori eradication
on gastric histology in patients on long-term NSAIDs is
unclear because of a paucity of data.
One of the most eﬀective and safest strategies to
prevent ulcers is cotherapy with proton pump inhibitors
(PPIs). However, profound acid suppressive therapy
changes the extent of H. pylori gastritis into a corpus-
predominant gastritis, which may accelerate the develop-
ment of gastric gland loss.15–17 The International Maastricht
guideline therefore advises to consider H. pylori eradication
in long-term PPI users.18 This is of relevance
for a considerable proportion of patients on long-term
NSAIDs who are cotreated with acid suppressive therapy
for many years. It is, however, unknown what the eﬀect is of
H. pylori eradication under these conditions.
Therefore we investigated, by means of a randomized,
double blind, placebo-controlled study, whether H. pylori
eradication changes gastric histology in patients receiving
long-term treatment with NSAIDs, both in patients with
and without gastroprotective cotreatment.
MATERIALS AND METHODS
Patients
Patients suﬀering from a rheumatic disease who were
between 40 and 80 years of age were eligible for the study ifCopyright r 2009 by Lippincott Williams & Wilkins
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they were using NSAID on a long-term basis and were
positive for H. pylori on serologic testing with enzyme-
linked immunosorbent assay. Long-term NSAID treatment
was deﬁned as the use of any NSAID for at least 3 days a
week during at least the previous month. Exclusion criteria
were previous eradication therapy for H. pylori, allergy for
the study medication (except amoxicillin) and presence of
severe comorbidity. Concurrent use of steroids, low-dose
aspirin, anticoagulants, and gastroprotective drugs were
allowed. The presence of IgG-antibodies to H. pylori was
determined with a commercial enzyme-linked immuno-
sorbent assay Pyloriset new EIA-G (Orion Diagnostica,
Espoo, Finland) according to the manufacturer’s instruc-
tions. This assay has been assessed in the population under
study and has proven a sensitivity and speciﬁcity in the
Netherlands of 98% to 100% and 79% to 85%, even
in patients on acid suppressive therapy.19–21 The study
protocol was approved by research and medical ethics
committees of all participating centers and all patients gave
written informed consent.
Study Design
After stratiﬁcation by concurrent use of gastroprotec-
tive agents (PPIs, H2 receptor antagonists, or misoprostol,
but not prokinetics or antacids), patients were randomly
assigned to receive either H. pylori eradication therapy with
omeprazole 20mg, amoxycillin 1000mg, and clarithromy-
cin 500mg (OAC) twice daily for 7 days or placebo.
Patients with an allergy for amoxycillin were randomized in
a separate stratum to receive omeprazole 20mg, metroni-
dazol 500mg, and clarithromycin 250mg (OMC) or
placebo therapy twice daily for 1 week. Randomization
to consecutive patient numbers was done in proportions
of 1:1, in blocks of 4 from a computer-generated list.
The study centers were provided with individually sealed
packages containing the treatment for each patient. Each
center received entire blocks to be used sequentially.
Rheumatologists were not practicing in more than one
center. The study medication was given in a double blind,
double dummy manner. Active and placebo preparations
were identical in appearance. The employees of the VU
University Medical Center pharmacy who packaged the
medication only knew the assignment. It was disclosed to
the treating physician only in case of emergency. All study
personnel and participants were blinded to treatment
assignment for the duration of the study.
Three months after study initiation patients underwent
endoscopy of the upper gastrointestinal tract. Endoscopic
ﬁndings were recorded systematically. The procedures were
performed without sedation, or under conscious sedation
using midazolam depending on patient’s preference. The
clinical results of the trial have been described elsewhere.22
Biopsies for histology and H. pylori culture were taken
with standard biopsy forceps form the antrum ( 4) and
the corpus ( 4). In the case of speciﬁc lesions additional
samples were obtained but these were not part of this study.
Histology
All biopsies were routinely strained with hematoxylin-
eosin. The slides were scored independently by an
experienced gastrointestinal pathologist (E.B.) and the
investigator (HdL), blinded to treatment assignment and
clinical data, according to the updated Sydney classiﬁca-
tion.23 Separate scores were given for H. pylori density,
acute and chronic inﬂammatory component of gastritis,
gastric glandular atrophy, and intestinal metaplasia. All
items were scored from 0 (absent), to 1 (mild), 2 (moderate),
or 3 (severe) as deﬁned in the Sydney classiﬁcation system.
In case of discrepant results, the specimen was discussed
until agreement was reached.
Statistical Analysis
The primary analysis was a comparison of treatment
arms, irrespective of H. pylori status of individual patients.
Measurements are expressed as mean and SD or as the
median and interquartile range. Diﬀerences between groups
were analyzed by w2 test and w2 test for linear trend (linear-
by-linear association). Another analysis compared out-
comes (the eﬀect of H. pylori eradication) between stratum
(the use of gastroprotective drugs or not) by computing
the homogeneity of the common odds ratio. The level of
signiﬁcance was set at P<0.05, 2 sided. SPSS software
(version 11.0.0) was used to perform all analyses.
RESULTS
Patients
Three hundred forty-seven H. pylori seropositive
patients were randomized in this study. A total of 172
received 1-week course of OAC whereas 175 received
placebo. The treatment groups were similar in terms of
demographic, rheumatic disease, drug use, and prognostic
variables (Table 1). Our eligibility criteria resulted in a
study group (61% women, mean age 59±10 y) with mainly
inﬂammatory rheumatic diseases, 48% of the patients used
one or two gastroprotective agent (77% PPI, 14% H2
TABLE 1. Baseline Characteristics of the 2 Groups (Eradication or
Placebo)
Characteristic
Eradication
(N=172)
Placebo
(N=175)
Age—y* 59±11 60±10
Women 108 (63) 104 (60)
Underlying disease
Rheumatoid arthritis 107 (62) 106 (61)
Spondylarthropathy 13 (8) 15 (9)
Psoriatic arthritis 14 (8) 11 (6)
Osteoarthritis 15 (9) 15 (9)
Other 23 (13) 28 (16)
Disease duration—yw 7 (3 to 14) 8 (3 to 15)
Gastroprotective treatment
H2 antagonist 9 (5) 14 (8)
PPI 64 (37) 63 (36)
Prostaglandin analogs
(misoprostol)
0 1 (1)
NSAID treatment
Conventional NSAID 118 (69) 116 (66)
COX-2 preferential NSAID
(meloxicam, nabumetone)
27 (16) 33 (19)
COXIB (rofecoxib, celecoxib) 17 (10) 13 (7)
Combination drug
(diclofenac/misoprostol)
10 (6) 13 (7)
Titer H. pylori serologyw 1590 (692-3536) 1846 (799-4057)
Ethnic Dutch white 130 (87) 133 (87)
Known allergy for amoxycillin 10 (6) 12 (7)
*Plus-minus values are means±SD; other values are counts (%) unless
noted.
wMedian (interquartile range).
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receptor antagonists, 15% misoprostol) in combination
with their NSAID therapy. No diﬀerences were noted
between the treatment arms in terms of protocol violations.
Histology
In 20 patients in the eradication group and 22 in the
placebo group gastric biopsies were not available for the
following reasons: 16 patients withdrew consent for
participation of the trial, 15 refused endoscopy, 7 used
anticoagulants prohibiting biopsy sampling according the
protocol, in 3 patients biopsy specimens could not be
obtained because of discomfort requiring early completion
of the procedure, and 1 patient died of cardiac arrest within
3 months after randomization. Histopathologic specimens
could be assessed from 305 patients: 152 patients in the
eradication group and 153 in the placebo group (Fig. 1).
Corpus
Corpus biopsy specimens were not available for 6
patients in the eradication group and 8 in the placebo
group. Complete data from 291 subjects were available
(as is shown in detail in Table 2 and Fig. 2). Corpus gastritis
activity was moderate to severe in 4% of patients in the
eradication group and in 35% of the placebo group
(P<0.001). Moderate to severe chronic inﬂammation was
present in 28% in the corpus of patients in the eradication
group. By comparison, moderate to severe chronic inﬂam-
mation was observed in 65% of the placebo group
(P<0.001). Overall, moderate to severe corpus glandular
atrophy was present in 10% of the eradication group and
22% of the placebo group (P=0.006). Intestinal metapla-
sia of the corpus mucosa did not diﬀer between groups and
was present in 6% of patients. H. pylori colonization of the
corpus mucosa was present in 11% of the eradication group
and in 71% of the placebo group (P<0.001).
Antrum
Antrum biopsy specimens were unavailable for 4
patients in the eradication group and 4 in the placebo
group. Accordingly, data from 297 patients were available
as shown in Table 3 and Figure 3. Antrum gastritis activity
was moderate to severe in 3% of the patients in the
eradication group and in 27% of the placebo group
(P<0.001). Moderate to severe chronic gastritis was
present in 51% in patients in the eradication group in the
antrum, and in 76% of the placebo group (P<0.001).
Antral glandular atrophy was scored moderate to severe in
33% in the eradication group and 41% in the placebo
group (no signiﬁcant diﬀerence). The presence of intestinal
metaplasia did not diﬀer between the groups in antrum and
was present in 17% of all patients. H. pylori colonization of
the antrum mucosa was present in 14% in the eradication
group and 62% in the placebo group (P<0.001).
Analysis of the Effect of Eradication Stratified
According to the use of Gastroprotective Drugs
Corpus
There were no diﬀerences between strata (according to
the use of gastroprotective drugs) for the eﬀect of
eradication on active gastritis in the corpus (P=0.27). A
signiﬁcant greater eﬀect of eradication was found in
patients on gastroprotective drugs for the presence of
moderate to severe chronic inﬂammation in the corpus
(22% and 74% in the eradication and placebo group,
respectively) than in patients who did not take gastro-
protective drugs (33% and 55% in the eradication and
placebo group, respectively) (P=0.007). No signiﬁcant
diﬀerence of eﬀect of eradication was found in patients for
the presence of corpus atrophy between patients using
gastroprotection (42% and 68% in the eradication and
placebo group, respectively) compared with in patients who
did not take gastroprotective drugs (53% and 58% in the
eradication and placebo group, respectively) (P=0.067).
There were no diﬀerences between strata for corpus
intestinal metaplasia (P=0.10). No diﬀerence was found
FIGURE 1. Trial profile and number of patients of whom
specimens were available. Data are number of patients.
TABLE 2. Histologic Characteristics of the Corpus, for Patients
Randomly Assigned to Eradication Therapy or Placebo
Variable Score
Eradication
(N=146)
Placebo
(N=145) P
Activity None 132 55 <0.001
Mild 9 39
Moderate 2 29
Severe 3 22
Inﬂammation None 7 3 <0.001
Mild 98 48
Moderate 30 60
Severe 11 34
Atrophy None 76 54 0.003
Mild 55 59
Moderate 12 28
Severe 3 4
Intestinal
metaplasia
None 136 139 0.257
Mild 6 4
Moderate 3 2
Severe 1 0
H. pylori
density
None 130 41 <0.001
Mild 6 28
Moderate 6 36
Severe 4 40
Data are number of patients.
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for eﬀect of eradication therapy between strata on the
presence of H. pylori (P=0.79).
Antrum
In the antrum, the eﬀect of eradication was not
modiﬁed by gastroprotective drugs on active gastritis
(P=0.81), chronic inﬂammation in the antrum
(P=0.99), antrum atrophy (P=0.59) nor antral intestinal
metaplasia (P=0.052). No diﬀerence was found for eﬀect
of eradication therapy between strata on the presence of
H. pylori (P=0.29).
DISCUSSION
The major ﬁnding of this large randomized, placebo-
controlled study in long-term NSAID-users was that
H. pylori eradication results in signiﬁcantly lower acute
and chronic gastritis scores despite ongoing NSAID use.
An additional remarkable ﬁnding was that corpus atrophy
scores were signiﬁcantly lower in the H. pylori eradication
group than in the placebo group.
Many studies have shown that eradication of H. pylori
causes resolution of active and chronic gastritis in non-
NSAID users.12–14 Various studies addressed the potential
interaction between H. pylori and NSAIDs on gastroduo-
denal mucosal damage. However, only few studies with
limited number of patients regarded the eﬀect of H. pylori
eradication on gastric histology in patients on NSAIDs. In
a small study of 11 H. pylori infected healthy subjects, high
dose of naproxen for only 4 days had no eﬀect on
polymorphonuclear cells nor on H. pylori density.24 A
similar ﬁnding was reported in a study of 52 patients with
rheumatoid arthritis who received NSAIDs for 1 month.
No diﬀerence in severity of gastritis was found between
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FIGURE 2. Gastritis scores for the corpus for eradication group and for the placebo group.
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H. pylori-positive and H. pylori-negative patients.25 In
addition, in 118 patients receiving chronic NSAID treat-
ment, the presence of H. pylori did not seem to increase
histologic damage or ulcer prevalence.26 In contrast,
another study found that the presence of neutrophils
increased the risk of ulceration in long-term NSAID users.
Most of the inﬂammatory cells were found in H. pylori-
positive patients. These patients had more severe gastritis
and were thus at higher risk for ulcer disease.27 Hence, these
studies point out that there is no agreement on the eﬀect of
H. pylori on histologic characteristics in NSAID users. The
present study with a high number of patients shows that
eradication of H. pylori leads to signiﬁcant reduction of
active and chronic inﬂammation of both corpus and
antrum mucosa within 3 months despite ongoing NSAID
therapy. These ﬁndings support the proposition that
H. pylori eradication might contribute to the prevention
of NSAID gastropathy in chronic NSAID users. However,
this seems not to be in line with data which are published
elsewhere.22 In that paper is described that H. pylori
eradication therapy in patients on long-term NSAID
treatment had no beneﬁcial eﬀect on the occurrence of
ulcers, ulcer complication, erosions, dyspepsia, or quality
of life. Nevertheless, the present study shows that H. pylori
eradication improves the degree of gastritis in patients who are
long term on NSAID treatment in the biopsy samples.
Whether this eﬀect has clinical consequences, such as the risk
of development of ulcers or cancer on the long term has to be
further investigated.
There is general agreement that acid suppressive
therapy changes the usually antral predominant gastritis
to one that is corpus predominant.28,29 In addition, from
studies of patients with gastro-esophageal reﬂux disease,
there is growing evidence that H. pylori eradication in PPI
users reduces mucosal inﬂammation and induces regression
of corpus glandular atrophy.15–17,30–32 These phenomena
are relevant because the pattern of gastritis, with or without
progression of gastric atrophy, is associated with an
increased risk for the development of gastric cancer.9 To
assess the potential beneﬁts of H. pylori eradication in this
setting, most studies are designed to examine regression of
precancerous changes, such as gland loss and intestinal
metaplasia of the gastric mucosa as surrogate end points. A
follow-up of many years would be necessary to conﬁrm
long-term clinical signiﬁcance of H. pylori eradication
for these premalignant parameters. Our data showed
indeed, in both patients with and without treatment with
gastroprotection, lower gastritis scores, and lower preva-
lence of atrophic gastritis of the corpus mucosa 3 months
after H. pylori eradication and a signiﬁcant greater eﬀect of
eradication on corpus inﬂammation in the gastroprotection
group than in those who were not receiving gastroprotec-
tion. In the absence of baseline biopsy samples, it is not
completely certain whether the diﬀerence is due to a
regression of atrophic gastritis but the probability that the
diﬀerences between groups was already present by chance
at baseline is very small, as the randomized groups are
large. A previous study showed a regression of atrophic
gastritis after H. pylori eradication in patients with reﬂux
esophagitis taking omeprazole maintenance therapy.16 The
ﬁrst follow-up in the latter study, however, took place 12
months after eradication therapy. Probably, the same eﬀect
at an earlier stage is found in this study. As a large number
of patients on long-term NSAIDs are treated with acid
suppressive therapy for many years, eradication ofH. pylori
in these patients may be advisable to heal gastritis, in
particular under the assumption that active gastritis
increases the risk for NSAID gastropathy. Eradication
may further prevent progression of atrophic gastritis, as its
eﬀect would be expected to persist.
Although the histopathology of H. pylori gastritis
is associated with well-deﬁned histologic features,23 the
spectrum and incidence of microscopic gastric lesions
caused by chronic ingestion of NSAIDs is unspeciﬁc and
still a matter of debate. Some investigators used Dixons’
system for chemical gastritis but no correlation was found
between the scoring system and endoscopic gastroduodenal
damage.26,33 Others concluded that there is no single
histologic feature that can be used to characterize the
diagnose chemical gastritis and simultaneous infection
by H. pylori and thus makes the histologic diagnosis
of chemical gastritis extremely diﬃcult.34 In this study,
interpretation of the gastric biopsies was made as uniform
and objective as possible by the use of predeﬁned criteria of
the updated Sydney System23 and by blinded assessment of
all biopsies by the same histopathologists.
We did not perform endoscopy at baseline, because
invasive screening tests for H. pylori are less feasible
in everyday practice. Instead, we used an assay for the
presence of IgG-antibodies toH. pylori. This assay has been
assessed in the population under study and has proven a
sensitivity and speciﬁcity in the Netherlands of 98% to
100% and 79% to 85%, even in patients on acid
suppressive therapy.19–21 We analyzed the data according
to treatment arm (intention to treat analysis). In practice
one might retreat patients in case patients remain H. pylori-
positive despite eradication therapy with antibiotics.
In conclusion, our study showed that H. pylori
eradication in patients on long-term NSAID therapy leads
to healing of gastritis despite ongoing NSAID therapy.
TABLE 3. Histologic Characteristics of the Antrum, for Patients
Randomly Assigned to Eradication Therapy or Placebo
Variable Score
Eradication
(N=148)
Placebo
(N=149) P
Activity None 126 66 <0.001
Mild 17 43
Moderate 4 27
Severe 1 13
Inﬂammation None 6 4 <0.001
Mild 66 32
Moderate 60 56
Severe 16 57
Atrophy None 9 4 0.181
Mild 90 84
Moderate 42 56
Severe 7 5
Intestinal
metaplasia
None 124 124 0.890
Mild 13 18
Moderate 8 5
Severe 3 3
H. pylori None 127 57 <0.001
Mild 9 22
Moderate 4 37
Severe 8 33
Data are number of patients.
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These data support the proposition that H. pylori eradica-
tion may reduce the severity of gastropathy in chronic
NSAID users.
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